Glactil

GLACTIV Tablet for Type 2 Diabetes Management

GLACTIV is a highly selective dipeptidyl peptidase 4 (DPP-4) inhibitor designed to help regulate blood sugar levels in patients with type 2 diabetes. This oral antidiabetic drug enhances the body’s natural incretin system, which helps control glucose levels by reducing the production of glucose in the liver and promoting the release of less glucagon when blood sugar is elevated.

Key Features:

• Once-a-Day Treatment: GLACTIV can be administered once daily, either before or after meals, without any food effect.
• Improved Glycemic Control: It effectively lowers HbA1c, postprandial hyperglycemic state, and fasting plasma glucose levels.
• Complementary Use: GLACTIV is recommended for patients who do not achieve adequate glycemic control with diet and exercise alone or in combination with other antidiabetic medications like sulfonylureas, thiazolidinediones, or biguanides.
• Stable Improvement: It provides stable improvement in glycemic control for up to 52 weeks.
• Safety Profile: Common adverse reactions include hypoglycemia and constipation, while laboratory abnormalities such as elevated ALT, AST, and gamma GPT were observed in some patients.

Available Dosages:

• 25 mg Tablet: 100 tablets (blister packaging and bottle), 420 tablets (blister packaging), 500 tablets (blister packaging).
• 50 mg Tablet: 100 tablets (blister packaging and bottle), 420 tablets (blister packaging), 500 tablets (blister packaging).
• 100 mg Tablet: 100 tablets (blister packaging and bottle), 420 tablets (blister packaging), 500 tablets (blister packaging).

Reimbursement Prices:

• 25 mg Tablet: JPY 99.50.
• 50 mg Tablet: JPY 185.70.
• 100 mg Tablet: JPY 278.60.

GLACTIV is a trusted medication for managing type 2 diabetes, offering a reliable and convenient solution for patients seeking to improve their glycemic control.